D. Western Therapeutics Institute Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yuichi Hidaka

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	15.9yrs
Participación del CEO	7.7%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	10.6yrs

Actualizaciones recientes de la dirección

Recent updates

Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

May 23

CEO

Yuichi Hidaka (51 yo)

15.9yrs

Permanencia

Mr. Yuichi Hidaka has been President of D.Western Therapeutics Institute, Inc.(DWTI) since December 2008 and serves as its Chief Executive Officer. Mr. Hidaka serves as a Director at Actual Eyes Inc. He se...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yuichi Hidaka	President	15.9yrs	sin datos	7.69% ¥ 286.4m
Sayako Matsubara	CFO & Director	1.7yrs	sin datos	0.015% ¥ 548.9k
Yoshiyuki Yamakawa	Independent Outside Director	14.7yrs	sin datos	0.047% ¥ 1.8m
Eisaku Nakamura	Independent Outside Director	6.6yrs	sin datos	0.00026% ¥ 9.7k
Masaaki Suzuki	Member of Scientific Advisory Board	no data	sin datos	sin datos
Tasuku Honjyo	Member of Scientific Advisory Board	no data	sin datos	sin datos
Masato Shibuya	Member of Scientific Advisory Board	no data	sin datos	sin datos
Arata Uemura	Member of Scientific Advisory Board	no data	sin datos	sin datos
Anthony Means	Member of Scientific Advisory Board	no data	sin datos	sin datos
Walter Chazin	Member of Scientific Advisory Board	no data	sin datos	sin datos
Yasuhiko Ito	Member of Scientific Advisory Board	no data	sin datos	sin datos
Yasumi Uchida	Member of Scientific Advisory Board	no data	sin datos	sin datos

10.6yrs

Permanencia media

56.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 4576 son experimentados ( 10.6 años antigüedad media).

D. Western Therapeutics Institute Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

Insufficient new directors

Insufficient new directors

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

Recent updates

D. Western Therapeutics Institute, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Second quarter 2024 earnings released: JP¥6.18 loss per share (vs JP¥4.73 loss in 2Q 2023)

New major risk - Share price stability

New minor risk - Shareholder dilution

Is D. Western Therapeutics Institute (TSE:4576) Using Debt Sensibly?

First quarter 2024 earnings released: JP¥9.96 loss per share (vs JP¥3.11 loss in 1Q 2023)

New minor risk - Shareholder dilution

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2024 Results on May 13, 2024

D. Western Therapeutics Institute, Inc. Provides Consolidated and Non Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

Full year 2023 earnings released: JP¥25.55 loss per share (vs JP¥14.47 loss in FY 2022)

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 27, 2024

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2023 Results on Feb 09, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: JP¥6.11 loss per share (vs JP¥3.94 loss in 3Q 2022)

New minor risk - Share price stability

D. Western Therapeutics Institute, Inc. to Report Q3, 2023 Results on Nov 10, 2023

Second quarter 2023 earnings released: JP¥4.73 loss per share (vs JP¥3.03 loss in 2Q 2022)

D. Western Therapeutics Institute, Inc. to Report Q2, 2023 Results on Aug 10, 2023

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024

First quarter 2023 earnings released: JP¥3.11 loss per share (vs JP¥0.71 loss in 1Q 2022)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023

Full year 2022 earnings released: JP¥14.47 loss per share (vs JP¥5.05 loss in FY 2021)

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 30, 2023

D. Western Therapeutics Institute, Inc. to Report Fiscal Year 2022 Results on Feb 13, 2023

Insufficient new directors

Third quarter 2022 earnings released: JP¥3.94 loss per share (vs JP¥0.65 loss in 3Q 2021)

D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: JP¥3.03 loss per share (vs JP¥1.40 loss in 2Q 2021)

D. Western Therapeutics Institute, Inc. announced that it has received ¥901.216203 million in funding from Whiz Partners Inc.

D. Western Therapeutics Institute, Inc. to Report Q2, 2022 Results on Aug 09, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Insufficient new directors

D. Western Therapeutics Institute, Inc. to Report Q1, 2022 Results on May 12, 2022

D. Western Therapeutics Institute, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

D. Western Therapeutics Institute, Inc., Annual General Meeting, Mar 29, 2022

D. Western Therapeutics Institute, Inc. to Report Q1, 2021 Results on May 13, 2021

D. Western Therapeutics Institute, Inc. to Report Q3, 2020 Results on Nov 12, 2020

D. Western Therapeutics Institute, Inc. announced that it has received ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm

CEO

Permanencia

Miembros de la Junta

Permanencia media

Promedio de edad